In ovarian cancer, BRCA1 mutation is constitutively associated with the activation of the NF-κB p65 subunit, and in OC treated with inhibitors of DNA damage repair, with activation of NF-κB p50 subunit, respectively. Here, NFKB1 is linked to ovarian cancer.